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A b s t r a c t
Background: Poland represents a country of high cardiovascular (CV) risk. The association between lipid abnormalities and 
increased CV risk is well established. Therefore, it is important to monitor the prevalence and control of dyslipidaemia. 
Aim: To evaluate serum lipids concentrations as well as the prevalence, awareness, and control of lipid abnormalities in 
a representative sample of adults in Poland.
Methods: In 2011, in a national cross-sectional survey blood samples were collected from 1168 males and 1245 females, 
aged 18–79 years, for measurement of total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), and triglycerides 
(TG) in blood serum. Low density lipoprotein cholesterol (LDL-C) was calculated using Friedewald’s formula.
Results: Mean serum TC concentration was 197.1 mg/dL (95% CI 193.8–200.4) in males (M) and 198.6 mg/dL (95% CI 
195.7–201.5) in females (F). Levels of LDL-C were 123.6 mg/dL (120.9–126.2) and 123.7 mg/dL (121.4–126.1), HDL-C 
— 45.8 mg/dL (44.7–47.0) and 54.1 mg/dL (53.1–55.1), TG — 140.9 mg/dL (133.0–148.8) and 104.0 mg/dL (99.8–108.2) 
for males and females, respectively. TC ≥ 190 mg/dL was found in 54.3% subjects (M 54.3%; F 54.4%). After adding patients 
on lipid-lowering treatment, hypercholesterolaemia was present in 61.1% of adults (M 60.8%; F 61.3%). LDL-C ≥ 115 mg/dL 
was detected in 57.8% of all subjects (M 58.3%; F 57.3%), while HDL-C < 40 mg/dL in 35.2% of males and < 45 mg/dL in 
22% of females TG ≥ 150 mg/dL was found in 21.1% of subjects (M 28.4%; F 14.0%). The highest prevalence of elevated TC 
and LDL-C levels was present in the age group of 40–59-year-olds. Of those with hypercholesterolaemia 58.7% (M 61.5%,  
F 56.0%) were not aware of the condition; 22.0% (M 21.0%, F 24.5%) were aware but were not being treated; 8.1% (M 7.7%, 
F 8.5%) were treated but with TC ≥ 190 mg/dL; and only 10.9% (M 10.7%, F 11.0%) were being treated with TC < 190 mg/dL.
Conclusions: The prevalence of dyslipidaemia in Poland continues to be high — over 60% of adults have hypercholesterol-
aemia, and control remains poor. The results of the NATPOL 2011 survey call for urgent preventive measures. 
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INTRODUCTION
Lipid disorders have long been considered a major risk factor 
for cardiovascular diseases (CVD). There is a strong positive 
association between the development of atherosclerosis and 
increased levels of total cholesterol (TC) or — more precisely 
— its main fraction, i.e. low density lipoproteins (LDL-C). This 
association is evident from prospective observational popula-
tion studies [1], premature clinical complications of familial 
hypercholesterolaemia [2], and a reduction in the rate of 
cardiovascular events, both fatal and non-fatal, as a result of 
lowering the levels of LDL-C following treatment with statins 
[3]. This final evidence, which indicates that a decrease in risk 
is directly proportional to the degree of reduction in LDL-C 
levels, also leads to the conclusion that the target in primary 
and secondary prevention should be set at very low LDL-C 
concentrations [4].
Another CVD risk factor is hypertriglyceridaemia, re-
lated to serum retention of very-low-density lipoprotein 
(VLDL) remnants, chylomicron remnants, and small VLDL 
particles [5]. These small lipoproteins contribute also to the 
development of atherosclerosis, under a mechanism similar to 
LDL. As shown by observational studies, low concentrations 
of high density lipoprotein cholesterol (HDL-C) increase the 
CVD risk, and, conversely, high concentrations of HDL-C have 
a preventive effect. However, these long-established facts are 
contradicted by the results of clinical trials where treatment 
leading to an increase in HDL-C concentrations was applied 
and where, despite the HDL-C increase, no decrease in the 
rate of cardiovascular episodes was recorded. This ‘HDL 
paradox’ was recently described in Polish literature [6, 7].
All this information on the role of lipoproteins as a risk 
factor provides a solid justification for nationwide population 
studies with regard to the incidence and management of lipid 
disorders in Poland, especially in light of changing dietary 
patterns and increasingly widespread use of statins. This risk 
factor was already assessed in several studies coded under 
the following acronyms: NATPOL-PLUS (2002; n = 3051; 
age 18–95) [8]; WOBASZ (2004–2007; n = 13545; age 
20–74) [9]; and POLSENIOR (2007–2010; n = 4949; age 
65–100) [10]. This paper is based on the results of the NAT-
POL 2011 survey (n = 2413; age 18–79) concerning the 
prevalence of lipid disorders in the adult Polish population, 
with controls for sex, age, body mass index (BMI), education 
level, and place of living, and it is also aimed at evaluating the 
efficiency of hypercholesterolaemia detection and treatment.
METHODS
The NATPOL 2011 survey (Arterial hypertension and other 
CVD risk factors in Poland; full Polish title: Nadciśnienie 
Tętnicze oraz inne czynniki ryzyka chorób serca i naczyń 
w Polsce) was a cross-sectional observational study aimed 
at assessing the prevalence and control of CVD risk factors 
in Poland, taken on a representative sample of Polish men 
and women aged 18–79 years. The detailed description 
of a three-stage sample selection procedure, examination 
methods used for assessment of existing risk factors, and the 
procedure for blood sample taking, storage, and transport 
to the central laboratory were all described in detail in an 
earlier paper [11]. 
The NATPOL 2011 survey was carried out between January 
and August 2011. The participation rate was 66.5% of those 
invited to enter the survey who met the inclusion criteria. As a re-
sult, in line with the study design assumptions, the total sample 
consisted of 2413 participants — 1168 men and 1245 women. 
Age distribution in the sample was as follows: 974 subjects aged 
18–39 years, 879 subjects aged 40–59 years, and 590 subjects 
aged 60–79 years. The gender and age structure of the sam-
ple corresponded to the structure of the Polish population in 
2010. Mean age was 44.9 ± 16 for men and 46.7 ± 17.2 for 
women. 1113 (46.1%) participants were residents of the coun-
tryside; 359 (14.9%) lived in towns < 50,000 residents; 
410 (17%) — in cities 50,000–200,000 residents; and 531 (22%) 
— in the largest cities > 200,000 residents. Elementary school, 
basic (post-primary vocational) education, and unfinished 
secondary was reported by 956 participants (39.6%); second-
ary and unfinished university-level — by 948 (39.3%); and 
university-level education — by 509 (21.1%).
Blood samples were collected at the patient’s home, after 
10–12 h of fasting. Frozen serum and plasma samples were 
transported to the central laboratory where analyses were 
performed. TC, HDL-C, LDL-C, and triglycerides (TG) in se-
rum were analysed with an Architect c8000 clinical chemistry 
analyser (Abbott Laboratories). Serum TC concentrations were 
determined by enzymatic method using cholesterol esterase 
and cholesterol oxidase; HDL-C — by using Accelerator Se-
lective Detergent causing accelerated non-HDL-C oxidation 
and HDL-C dissolving; LDL-C concentrations were calculated 
using Friedewald’s formula: LDL-C [mg/dL] = TC [mg/dL] 
– HDL-C [mg/dL] – TG [mg/dL]/5. 
Where TG concentrations were greater than 400 mg/dL, 
Friedewald’s formula was not used. TG concentrations were 
determined by enzymatic method using glycerol kinase and 
glycerol-3-phosphate oxidase. Serum levels of apolipopro-
tein A1 and apolipoprotein B (apo B) were determined by 
immunonephelometry, and the results will be discussed in 
a separate publication.
Hypercholesterolaemia was defined as either measured 
TC concentrations ≥ 190 mg/dL (≥ 5.0 mmol/L) or taking 
statins/fibrates. Increased LDL-C was diagnosed for concen-
trations ≥ 115 mg/dL (≥ 3.0 mmol/L). Abnormalities in serum 
levels of HDL-C were defined as concentrations < 45 mg/dL 
(< 1.2 mmol/L) in women and < 40 mg/dL (< 1.0 mmol/L) 
in men. Increased TG concentrations were defined at lev-
els ≥ 150 mg/dL (≥ 1.7 mmol/L). The criteria for diagnosing 
abnormal lipid and lipoprotein concentrations are in line with 
the guidelines of the European Society of Cardiology [4, 12].
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Statistical analyses were carried out using the following 
software packages: SAS for Windows (ver. 9.1.3.) and R (The 
R Foundation). Basic statistical analyses involving estimation of 
the indicators defined in the study objectives were conducted 
using the procedures of SURVEYFREQ and SURVEYMEANS 
of the SAS package, taking into account the design effect of 
the survey.
The NATPOL 2011 survey was approved by the Bioethics 
Commission of the Medical University of Gdansk.
RESULTS
As shown in Table 1, mean concentrations of TC and LDL-C 
in men were 197.1 mg/dL (95% CI 193.8–200.4) and 
123.6 mg/dL (120.9–126.2), respectively. The correspond-
ing values in women were 198.6 mg/dL (195.7–201.5) and 
123.7 mg/dL (121.4–126.1). The highest mean concentrations 
of TC and LDL-C are found in middle-aged men and women 
(age group: 40–59 years). In this age range, TC concentra-
tion values were as follows: 212.4 mg/dL (208–216.8) for 
men, and 214.4 mg/dL (210–218.8) for women, but LDL-C 
concentrations were: 135.1 mg/dL (131.5–138.8) for men 
and 137.2 mg/dL (133.2–141.1) for women. Mean HDL-C 
concentrations in men were lower than in women (45.8 mg/dL 
[44.7–47.0] vs. 54.1 mg/dL [53.1–55.1]), respectively. This was 
true for all age groups. The difference in concentrations of this 
lipid between sexes were not dependent on age. Men had 
higher mean TG concentrations than women — 140.9 mg/dL 
(133–148.8) vs. 104 mg/dL (99.8–108.2). This difference 
applied to the 18–39 and 40–59 age groups, whereas TG 
concentrations in the 60–79 age group were similar for both 
males and females. 
From Table 2, which shows the percentage distribution 
of TC concentrations, we can find that TC ≥ 190 mg/dL was 
found in 54.3% subjects. There is no difference in this re-
spect between male and female subjects (54.3% vs. 54.4%). 
Severe hypercholesterolaemia (TC ≥ 310 mg/dL) was seen in 
0.8% of men and 0.6% of women. Hypercholesterolaemia 
was most often found in those aged 40–59 years (71.6%). In 
older subjects (age group: 60–79) increased concentrations 
of TC were less frequently found (59.3%); and even less often 
within the oldest sub-group (age: 65–79; 54.3%). Overweight 
(BMI 25–29.9 kg/m2) or obese subjects (BMI ≥ 30 kg/m2) 
suffered from hypercholesterolaemia more often than those 
with BMI < 25 kg/m2. The corresponding percentages are: 
61.9%, 61%, and 44.6%. The frequency of increased TC con-
centrations was higher in those with primary or post-primary 
vocational education (57.8%), compared to subjects with 
secondary (52.1%) or higher (53%) education.
When statin/fibrate use was included in the analysis, 
hypercholesterolaemia was found in 61.1% of subjects (95% 
CI 58.2–63.9%): in men: 60.8% (95% CI 56.4–65.1%); in 
women: 61.3% (95% CI 57.4–65.1%); twice as often in the 
40–59 and 60–79 age groups (correspondingly: 76.6% and 
82.9%) than in the 18–39 age group (38%) (Table 3). If we 
estimate the population of Poles aged 18–79 years to be 
about 29,398,000 (based on Central Statistical Office data), 
we can estimate that the number of patients with hyper-
cholesterolaemia in this broad age range stands at approx. 
17,954,000 (95% CI 16,420–19,489 million). The incidence 
of hypercholesterolaemia is higher in overweight or obese 
people (69.3% and 74.2%, respectively), compared to those 
with BMI < 25 kg/m2 (46.5%). Hypercholesterolaemia was 
detected in 66.3% of those with elementary or vocational 
education, 57.5% of people with secondary education, and 
59.2% of people with higher education.
Increased serum concentrations of LDL-C (≥ 115 mg/dL) 
were found in 57.8% of the population under study (Table 4) 
and the results are similar for men and women (58.3% and 
57.3%, respectively). LDL-C < 100 mg/dL (2.5 mmol/L) was 
found in 25.8% of the population (male [M] 26.3%, female 
[F] 25.2%). These concentrations of LDL-C are considered 
Table 1. Mean values of serum total cholesterol, low density 
lipoprotein cholesterol (LDL-C), high density lipoprotein  




Men (n = 1168) Women (n = 1245)
Total cholesterol [mg/dL]
18-39 184.7 (180.1–189.3) 180.5 (177.1–183.9)
40-59 212.4 (208–216.8) 214.4 (210–218.8)
60-79 194.7 (187.9–201.4) 207.4 (202.1–212.7)
All (18–79) 197.1 (193.8–200.4) 198.6 (195.7–201.5)
LDL-C [mg/dL]*
18-39 113.1 (109.4–116.8) 109.1 (106.1–112.1)
40-59 135.1 (131.5–138.8) 137.2 (133.2–141.1)
60-79 124.8 (119.2–130.4) 129.9 (125–134.7)
All (18–79) 123.6 (120.9–126.2) 123.7 (121.4–126.1)
HDL-C [mg/dL]
18-39 44.7 (43.2–46.2) 54.3 (53–55.5)
40-59 47.3 (45.4–49.3) 54.7 (52.7–56.6)
60-79 45.3 (43.2–47.3) 52.8 (50.9–54.6)
All (18–79) 45.8 (44.7–47) 54.1 (53.1–55.1)
Triglycerides [mg/dL]
18-39 136.2 (123.9–148.4) 85.6 (82–89.3)
40-59 154.4 (141.2–167.6) 113 (105.1–121)
60-79 122.3 (112.5–132.1) 125.2 (118.5–132)
All (18–79) 140.9 (133–148.8) 104 (99.8–108.2)
*The results of LDL-C were calculated using Friedewald’s formula only 
when the triglyceride concentration was < 400 mg/dL (< 4.5 mmol/L). 
The results are given as mean values. In parentheses are 95% confiden-
ce intervals (95% CI). The results include the design effect — DEFF. To 
obtain blood cholesterol and triglycerides in mmol/L divide concentra-
tions in mg/dL by 38.5 and 88.5, respectively.
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Table 2. The percentage of studied subjects (%) by serum total cholesterol intervals 
< 175 mg/dL 175–189 mg/dL 190–239 mg/dL 240–309 mg/dL ≥ 310 mg/dL
All
The percentage in each interval 30.7% 14.9% 38.4% 15.2% 0.7%
The cumulated percentage 30.7% 45.7% 84.1% 99.3% 100.0%
By age 
18-39 years 46.0% 16.8% 30.0% 6.9% 0.3%
40-59 years 15.4% 13.0% 47.7% 22.8% 1.1%
60-79 years 26.2% 14.4% 39.3% 19.1% 0.9%
By gender*
Men 33.1% 12.6% 38.3% 15.2% 0.8%
Women 28.5% 17.1% 38.6% 15.2% 0.6%
By body mass index [kg/m2]
< 25.0 38.1% 17.2% 32.7% 11.5% 0.4%
25.0-29.9 26.3% 11.8% 41.6% 19.0% 1.3%
≥ 30.0 25.8% 13.2% 44.1% 16.3% 0.6%
By education
Primary or basic 28.5% 13.7% 40.0% 16.8% 1.0%
Secondary or incomplete higher 32.6% 15.3% 37.7% 13.8% 0.6%
Higher 30.8% 16.1% 37.3% 15.3% 0.4%
By place of residence
Village or towns < 50,000 29.3% 13.7% 40.5% 15.6% 0.9%
Towns 50,000–200,000 35.7% 17.7% 30.9% 15.4% 0.2%
Towns > 200,000 30.4% 15.8% 39.1% 13.8% 0.9%
*Mann-Whitney test to compare the differences in distribution between men and women: p = 0.219. To obtain blood cholesterol in mmol/L 
divide concentrations in mg/dL by 38.5. 
optimal for healthy people. LDL-C < 70 mg/dL (< 1.8 mmol/L) 
was found in 4% of the population (M: 5.2%, F: 2.9%) and 
LDL-C < 55 mg/dL (< 1.4 mmol/L) — in 0.9% of the popula-
tion (M: 0.9%, F: 0.9%). On the other hand, 3.8% of people 
had LDL-C levels ≥ 190 mg/dL (M: 3.4%, F: 4.2%). The high-
est incidence of increased LDL-C levels was found in the 
40–59 age group (72.5%), similarly as in the case of increased 
TC (71.6%). Similarly to TC ≥ 190 mg/dL, the incidence of 
LDL-C ≥ 115 mg/dL was lower in people 60–79 years old. 
Overweight and obesity were linked to a higher proportion of 
people with increased LDL-C (65.4% and 63.7%), compared 
to those with normal body weight (48.1%). In our survey 
education had no association with increased LDL-C levels.
Low concentrations of HDL-C (Table 5) were found in 
35.2% of men and 22% of women (low HDL-C is diagnosed 
at < 40 mg/dL in men and < 45 mg/dL in women). High 
HDL-C concentrations (≥ 60 mg/dL) were found in women 
more than twice as often as in men (28.0% vs. 13.3%). No 
significant association of age and hypoalphalipoproteinaemia 
was detected (neither for HDL-C < 40 mg/dL nor < 45 mg/dL). 
Low HDL-C was more often found in overweight and obese 
people, compared to those with BMI < 25 kg/m2 (respective 
figures: 27.4%, 31.7%, and 13% for HDL-C < 40 mg/dL; and 
43%, 53.2%, and 24.4% for HDL-C < 45 mg/dL). Higher 
proportions of low HDL-C were observed in people with 
elementary/vocational or secondary education, compared 
to those with higher education (respective concentrations: 
22.4% and 24.8% vs. 18% for HDL-C < 40 mg/dL; 39.3% 
and 39.5% vs. 33% for HDL-C < 45 mg/dL).
Hypertriglyceridaemia (TG ≥ 150 mg/dL) was found in 
21.1% of the study population (Table 6). Increased TG con-
centrations were found twice as often in men (28.4%) com-
pared to women (14.0%). Very high TG levels (≥ 400 mg/dL; 
4.5 mmol/l) were found in 3.1% of male and 0.2% of female 
subjects. Hypertriglyceridaemia affected overweight and 
obese individuals more often (23.9% and 36.2%, respectively) 
than those with BMI < 25 kg/m2 (10.4%). Hypertriglyceridae-
mia occured more often in those with elementary/vocational 
and secondary education (21.9% and 21.8%), compared to 
people with higher education (18.1%).
Data on the management of hypercholesterolaemia in 
Poland in 2011 are shown in Tables 7 and 8). Table 7 shows 
that among those with hypercholesterolaemia 58.7% were 
unaware of the condition (M: 61.5%, F: 56%), 22.4% were 
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aware but not in treatment (M: 20.1%, F: 24.5%), 8.1% were 
treated but not effectively (TC ≥ 190 mg/dL, M: 7.7%, F: 8.4%), 
and only 10.9% were treated effectively (TC < 190 mg/dL, 
M: 10.7%, F: 11%). The largest proportions of patients who 
are aware of hypercholesterolaemia (57.5%), undergoing 
treatment for the condition (40.1%), with good control among 
all individuals with hypercholesterolaemia (28.2%), and 
with good management of the condition among all people 
treated (70.3%), were found in individuals aged 60–79 years 
(Table 8). Those more aware of hypercholesterolaemia were 
overweight and obese individuals (33.4% and 49.6%, re-
spectively), compared to those with BMI < 25 kg/m2 (24%). 
In the group of overweight and obese people there was also 
a higher proportion of people treated for hypercholesterol-
aemia (18.7% and 29.8% vs. 8.1%) and a better control of 
cholesterol concentrations.
Table 9 shows that of the risk factors associated with 
hypercholesterolaemia, the factor with the greatest impact 
was age: odds ratio (OR) for people aged 40–59 (vs. 18–39) 
was 4.76 (3.85–5.87), while OR for those aged 60–79 it was 
(vs. 18–39) 6.52 (4.87–8.72). There was also an association 
between hypercholesterolaemia and overweight and obesity: 
OR 1.75 (1.41–2.17) and 1.86 (1.43–2.42), respectively. 
Gender had no impact on hypercholesterolaemia.
DISCUSSION
Compared to the 2002 NATPOL PLUS survey [8], mean TC 
concentrations in the population of Polish adults decreased 
during nine years, from 205.1 mg/dL to 197.1 mg/dL among 
men and from 207.2 mg/dL to 198.6 mg/dL among women. 
It should be noted that the 2002 survey was conducted 
on a population sample of 18–94-year-olds, whereas the 
2011 sample included respondents aged 18–79 years; how-
ever, data collected in 2002 on TC and LDL-C levels are split 
between sexes and age groups; therefore, it is possible to 
compare the results of the two surveys. A considerable de-
crease in TC levels was specifically observed in people aged 
60 years or older (M: from 211.6 mg/dL to 194.7 mg/dL; 
F: from 232.6 mg/dL to 207.4 mg/dL). Similarly, LDL-C levels 
in this age group have also decreased (M: from 132.8 mg/dL 
to 124.8 mg/dL; F: from 145.1 mg/dL to 129.9 mg/dL). In the 
40–59 age group there has been practically no change in TC 
and LDL-C concentrations. The likely cause for the decrease 
in TC and LDL-C levels in subjects aged 60–79 may be the 
more widespread use of statin therapy in this age group in 
the years 2002–2011 [13]. Data from Intercontinental Manu-
facturing Services Health show a large increase in statin sales 
in the period, but data on specific age groups are lacking. 
The decrease in TC and LDL-C levels cannot be explained 
by favourable changes in Polish dietary patterns (a markedly 
reduced intake of animal fats and an increased consumption 
of vegetable fats), because these changes occurred primarily 
in the first decade after 1991 [14] and that was the period 
when they could have had an impact on population levels of 
TC and LDL-C. After that period dietary changes were only 
small. It is a disconcerting finding that the highest TC and 
LDL-C concentrations are found in the middle-aged group 
(40–59 years old).
Similar results were obtained in surveys carried out in 
the United States, Canada, and Germany. In the NHANES 
survey (National Health and Nutrition Examination Survey), 
carried out in 1999–2000 on a sample of 4115 adults aged 
20 years and older, mean TC levels in the entire population 
were 205.6 mg/dL (F) and 202.9 mg/dL (M), but they reached 
the level of 235.2 mg/dL in women aged 55–74 years and 
215.6 mg/dL in men aged 45–64 years [15]. In the German 
DEGS1 survey (German Health Interview and Examination 
Survey for Adults), taken in 2008–2010 on a sample of about 
7000 people aged 18–79 years, the mean TC concentrations 
Table 3. The prevalence of hypercholesterolaemia (total cho-
lesterol > 190 mg/dL or statins/fibrates use) in Poland by age, 
gender, body mass index, education, and place of residence 
Subjects with  
hypercholesterolaemia 
— prevalence in  





All 61.1 (58.2–63.9) 1504
By age
18-39 years 38.0 (33.9–42.2) 385
40-59 years 76.6 (73.2–79.7) 648
60-79 years 82.9 (78.6–86.5) 471
By gender
Men 60.8 (56.4–65.1) 734
Women 61.3 (57.4–65.1) 770
By body mass index [kg/m2]
< 25.0 46.5 (42.4–50.7) 481
25.0-29.9 69.3 (64.6–73.7) 502
≥ 30.0 74.2 (69.6–78.4) 413
By education




Higher 59.2 (54.2–64.1) 298







Towns > 200,000 59.5 (54.4–64.4) 326
The results after weighing in relation to age and sex structure of the 
population of adult Poles in 2011. The results include the design  
effect — DEFF.
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were 205.1 mg/dL (F) and 200.1 mg/dL (M) [16]. In a study 
using the data from the Canadian Primary Care Sentinel Sur-
veillance Network for a population of more than 128,000 Ca-
nadians aged 20 years and older, the mean level of TC was 
191.9 mg/dL, and LDL-C — 112.2 mg/dL [17]. Lower levels 
of serum cholesterol were detected in a study carried out in 
Saudi Arabia on a population of about 4500 people, but the 
study included individuals aged 15 years and older. Mean TC 
levels were 172.1 mg/dL in females and 173.6 mg/dL in males, 
and LDL-C — 107.0 mg/dL and 106.3 mg/dL, respectively 
[18]. The levels of TC found in the NATPOL 2011 survey are 
close to the levels found in the populations of developed 
North American and European countries.
Hypercholesterolaemia is the most prevalent risk factor in 
the Polish population: 61.1% of Polish adults have hypercholes-
terolaemia (this includes people with TC ≥ 190 mg/dL and those 
who take hypolipidaemic agents). When hypercholesterolaemia 
is diagnosed on the basis of serum TC levels only, it is found in 
54.3% of Polish adults. This means that the frequency of hy-
percholesterolaemia defined as TC ≥ 190 mg/dL has decreased 
over the past nine years: in 2002, when diagnosed on the basis 
of serum TC levels only, it was found in 60.7% of the study 
population [8]. The group with the highest incidence rate of hy-
percholesterolaemia (82.9%) are those aged 60–79 years. This 
incidence rate covers both those with TC ≥ 190 mg/dL and/or 
those who take hypolipidaemic drugs (the proportion of people 
on lipid-lowering drugs is largest in this age group).
The frequency of hypercholesterolaemia (TC ≥ 200 mg/dL) 
measured in the 1999–2000 NHANES survey was 50.9% in 
women and 50.4% in men. Hypercholesterolaemia, defined 
as TC > 200 mg/dL and/or use of hypolipidaemic drugs, was 
found in 53.5% of women and 55.7% of men, and TC levels 
for both sexes peaked in the 64–74-year age group [15]. A hy-
percholesterolaemia frequency similar to Poland was detected 
in the German DEGS1 survey — TC levels > 190 mg/dL were 
found in 60.5% of women and in 56.5% of men [16]. The 
results of the survey taken in Saudi Arabia differ strongly from 
the results obtained in Poland and Germany. In the Saudi 
Arabian survey TC levels > 200 mg/dL were found in 19.9% 
of women and in 18.7% of men [18].
Results of the surveys confirm the established association 
of HDL-C levels with overweight and obesity. In the 2011 
Table 4. The percentage of studied subjects (%) by serum low density lipoprotein cholesterol intervals 










≥ 190  
mg/dL
All
The percentage in each interval 4.0% 21.8% 16.4% 40.7% 13.3% 3.8%
The cumulated percentage 4.0% 25.8% 42.2% 82.9% 96.2% 100.0%
By age
18-39 years 6.3% 30.6% 20.5% 35.9% 5.7% 1.1%
40-59 years 1.3% 12.9% 13.3% 45.7% 20.5% 6.3%
60-79 years 4.3% 19.0% 13.4% 41.6% 16.6% 5.1%
By gender*
Men 5.2% 21.1% 15.4% 41.1% 13.8% 3.4%
Women 2.9% 22.3% 17.5% 40.4% 12.7% 4.2%
By body mass index [kg/m2]
< 25.0 5.3% 28.2% 18.0% 36.0% 9.0% 3.4%
25.0-29.9 2.7% 16.7% 15.0% 43.1% 16.7% 5.6%
≥ 30.0 3.7% 20.0% 12.6% 45.6% 16.1% 2.0%
By education
Primary or basic 4.5% 21.1% 15.8% 38.5% 16.1% 4.0%
Secondary or incomplete higher 4.3% 21.2% 17.4% 41.9% 12.1% 3.2%
Higher 2.6% 23.9% 15.7% 42.0% 11.0% 4.8%
By place of residence
Village or towns < 50,000 3.9% 21.8% 15.3% 40.7% 14.5% 3.8%
Towns 50,000–200,000 5.1% 22.2% 18.2% 38.6% 12.4% 3.5%
Towns > 200,000 3.1% 21.4% 17.9% 42.7% 10.9% 4.1%
*Mann-Whitney test to compare the differences in distribution between men and women: p = 0.910. Subjects with serum triglycerides ≥ 400 mg/dL  
were excluded from the analysis. To obtain blood cholesterol in mmol/L divide concentrations in mg/dL by 38.5.
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NATPOL survey low concentrations of HDL-C were found in 
22% of women and in 35.2% of men. This is similar to the re-
sults of the 2003–2006 NHANES survey — 23.3% at the same 
cutoff points [19], but it was much higher than the results of 
DEGS1. In the German survey HDL-C levels < 40 mg/dL were 
found in 3.6% of women and in 19.3% of men [16]. When 
analysing these differences, one should take into account 
the specific profile of each population and the differences in 
methods used to measure HDL-C levels.
Hypertriglyceridaemia (TG > 150 mg/dL) is found in 21.7% 
of the Polish population (M: 28.4%, F: 14%), and more often 
in people classified as overweight and obese. The frequency 
of hypertriglyceridaemia in the 2003–2006 NHANES survey 
was slightly higher — 29.6% [19]. It should be emphasised that 
mean levels of LDL-C and TG are higher in men and women 
in the 40–59 age group, compared to other age groups. Con-
sidering the high prevalence of lipid disorders in people aged 
40–59 years, we conclude that this age group carries the highest 
risk of CVD. It should be also kept in mind that LDL-C was iden-
tified as the primary lipid analysis (Class I of recommendations) 
for lipid screening and control [4]. Apo B should be considered 
an alternative risk marker, especially in patients with combined 
hyperlipidaemia, diabetes, metabolic syndrome, and chronic 
kidney disease (Class IIa of recommendation with C level of 
evidence), whereas control of apo B levels is considered to be 
a secondary treatment target (Class IIa B).
The data concerning control of hypercholesterolaemia in 
Poland, obtained in the 2011 NATPOL survey, should send 
a warning message. Almost 60% of patients with hypercho-
lesterolaemia are unaware of their condition, one person in 
five knows about it but does not take any treatment, 8% of 
patients take some medication but it is not effective, and only 
about 11% are on an effective treatment regime. However, 
the control of dyslipidaemia is not a problem limited just to 
Poland. Similar data were obtained in surveys carried out in 
other countries. In the 1999–2000 NHANES survey 65% of 
subjects with hypercholesterolaemia (the condition was de-
fined as it was in NATPOL) were unaware of their disease, 12% 
were in treatment, and only 5.4% were on an effective treat-
ment regime [15]. In the DEGS1 survey, it was established that 
72.4% of the German population with TC levels > 190 mg/dL 
are not aware of their hypercholesterolaemia [16].
A telling example for the importance of cholesterol level 
reduction in the prevention of CVDs is the IMPACT model, 
Table 5. The percentage of studied subjects (%) by serum high density lipoprotein cholesterol intervals 
< 40 mg/dL 40–44 mg/dL 45–49 mg/dL 50–59 mg/dL ≥ 60 mg/dL
All
The percentage in each interval 22.5% 15.6% 15.3% 25.8% 20.8%
The cumulated percentage 22.5% 38.1% 53.4% 79.2% 100.0%
By age 
18-39 years 23.2% 16.4% 14.7% 26.3% 19.3%
40-59 years 21.9% 14.3% 15.1% 25.0% 23.7%
60-79 years 22.1% 16.3% 17.0% 26.1% 18.5%
By gender*
Men 35.2% 19.6% 14.5% 17.3% 13.3%
Women 10.4% 11.8% 16.1% 33.7% 28.0%
By body mass index [kg/m2]
< 25.0 13.0% 11.4% 14.9% 31.0% 29.7%
25.0-29.9 27.4% 15.6% 16.2% 23.3% 17.4%
≥ 30.0 31.7% 21.5% 17.1% 18.3% 11.4%
By education
Primary or basic 22.4% 16.9% 14.6% 25.1% 21.0%
Secondary or incomplete higher 24.8% 14.7% 15.4% 25.8% 19.3%
Higher 18.0% 15.1% 16.3% 26.9% 23.7%
By place of residence
Village or towns < 50,000 20.6% 17.0% 14.8% 26.4% 21.2%
Towns 50,000–200,000 27.9% 14.7% 18.4% 21.2% 17.7%
Towns > 200,000 23.1% 12.3% 14.2% 27.8% 22.5%
*Mann-Whitney test to compare the differences in distribution between men and women: p < 0.001. To obtain blood cholesterol in mmol/L 
divide concentrations in mg/dL by 38.5.
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which shows that the decline in coronary heart disease mor-
tality in Poland over the period of 1991–2005 (reduction by 
26,200 coronary deaths) can be credited in 39% to a decrease 
in TC levels [20]. In the first years following 1991, the decrease 
in cholesterol levels are probably attributed to considerable 
favourable changes in the structure of fats consumed by the 
population [14], but in subsequent years the primary impact 
resulted probably from an increased use of hypolipidaemic 
drugs because dietary patterns ceased to change.
CONCLUSIONS
The NATPOL survey is not only a rich source of data con-
cerning the prevalence of CVD risk factors in the population 
of adult Poles, including lipid disorders, but it also opens an 
Table 6. The percentage of studied subjects (%) by serum triglycerides intervals 
< 150 mg/dL 150–199 mg/dL 200–399 mg/dL ≥ 400 mg/dL
All
The percentage in each interval 79.0% 10.4% 9.0% 1.7%
The cumulated percentage 79.0% 89.4% 98.3% 100.0%
By age 
18-39 years 83.6% 8.1% 6.7% 1.6%
40-59 years 74.3% 12.2% 11.4% 2.1%
60-79 years 77.6% 12.2% 9.3% 0.9%
By gender*
Men 71.5% 12.8% 12.5% 3.1%
Women 86.0% 8.2% 5.6% 0.2%
By body mass index [kg/m2]
< 25.0 89.5% 6.1% 4.0% .3%
25.0-29.9 76.1% 11.3% 10.1% 2.5%
≥ 30.0 63.8% 17.1% 16.1% 3.0%
By education
Primary or basic 78.1% 10.0% 9.7% 2.2%
Secondary or incomplete higher 78.1% 11.1% 9.6% 1.1%
Higher 82.0% 9.8% 6.5% 1.8%
By place of residence
Village or towns < 50,000 78.0% 10.7% 9.9% 1.4%
Towns 50,000–200,000 82.1% 7.6% 9.0% 1.4%
Towns > 200,000 78.8% 12.1% 6.6% 2.5%
*Mann-Whitney test to compare the differences in distribution between men and women: p < 0.001. To obtain blood triglycerides in mmol/L 
divide concentrations in mg/dL by 88.5.
Table 7. Awareness, treatment, and control of hypercholesterolaemia in Poland
The percentage (%) of patients with 
TC ≥ 190 mg/dL, who are not treated
The percentage (%) of patients  
on statins or fibrates
Unaware of high chole-
sterol (newly detected)
Aware of high chole-
sterol but not treated
Treated unsuccessfully: 
TC ≥ 190 mg/dL
Treated successfully: 
TC < 190 mg/dL
All (100% patients) 58.7 (54.9–62.4 ) 22.4 (19.7–25.2 ) 8.1 (6.2–10.5 ) 10.9 (8.9–13.2 )
By gender
Men 61.5 (56.7–66.1) 20.1 (16.9–23.6) 7.7 (5.4–10.9 ) 10.7 (8.4–13.5)
Women 56 (50.6–61.3) 24.5 (20.7–28.7) 8.4 (5.8–12.2) 11 (8.1–14.9)
TC — total cholesterol; Hypercholesterolaemia is defined as serum TC ≥ 190 mg/dL and/or hypolipidaemic medication i.e. statin/fibrate (regardless 
of the level of TC). The results after weighing in relation to age and sex structure of the population of adult Poles in 2011. The results include the 
design effect — DEFF. Comparison of the distribution between men and women — c2 test: p = 0.152.
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opportunity to measure and evaluate changes that occurred in 
this field over the period between 2002 and 2011. The com-
parison between these two points in time provides valuable 
information on the effectiveness of preventive actions. Even 
though the situation concerning the prevalence of lipid dis-
orders has improved, the incidence of these disorders in the 
population remains high. This indicates that intensive efforts 
are required to improve the detection and management of 
these disorders, especially because that is a cost-effective way 
in which coronary episodes may be prevented. The NATPOL 
survey could serve as a model base survey to monitor the 
CVD risk factors, and as such, should be regularly run at 
predetermined cycles.
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Table 8. Awareness, treatment, and control of hypercholesterolaemia depending on the age and body mass index
The percentage  
of aware among  
all patients
The percentage  
of treated among  
all patients
The percentage of good 
control: TC < 190 mg/dL 
among all patients
The percentage of good 
control: TC < 190 mg/dL 
among all treated
Age
18-39 years 11.1 (8.3–14.6) 2.8 (1.4–5.5) 1.8 (0.7–4.6) 65.7 (33.1–88.2)
40-59 years 39.3 (34.4–44.4) 16.6 (12.8–21.3) 6.5 (4.7–9.1) 39.4 (30.5–48.9)
≥ 60 years 57.5 (49.8–64.8) 40.1 (34.8–45.7) 28.2 (22.9–34.2) 70.3 (61.3–78)
P < 0.001 < 0.001 < 0.001 < 0.001
By body mass index [kg/m2]
< 25.0 24 (20.1–28.3) 8.1 (5.8–11.2 ) 3.9 (2.2–6.7) 47.9 (31.7–64.6)
25.0-29.9 33.4 (28.4–38.9) 18.7 (14.7–23.4) 10.7 (8–14) 57.1 (46.8–66.7)
≥ 30.0 49.6 (43–56.2) 29.8 (23.8–36.6) 17.5 (13.7–22.2) 58.9 (49.9–67.2)
P < 0.001 < 0.001 < 0.001 0.467
Hypercholesterolaemia is defined as serum total cholesterol ≥ 190 mg/dL and/or hypolipidaemic medication i.e. statin/fibrate (regardless of the 
level of total cholesterol).
Table 9. Multivariate logistic regression to estimate the odds of hypercholesterolaemia for each of the factors after correction by 
other variables
Factor Odds ratio 95% CI
Age the reference group: 18–39 years
40-59 vs. 18-39 years 4.76 3.85–5.87
60-79 vs. 18-39 years 6.52 4.87–8.72
Gender the reference group: women
Man vs. woman 0.94 0.77–1.14
BMI the reference group: BMI < 25 kg/m2
Overweight (BMI 25-25.99 kg/m2) vs. subjects with BMI < 25 kg/m2 1.75 1.41–2.17
Obesity (BMI ≥ 30 kg/m2) vs. subjects with BMI < 25 kg/m2 1.86 1.43–2.42
Education the reference group: subjects with higher education
Primary or basic vs. higher 0.77 0.6–1.01
Secondary vs. higher 0.75 0.59–0.95
R2 0.240
Hypercholesterolaemia is defined as serum total cholesterol ≥ 190 mg/dL and/or hypolipidaemic medication i.e. statin/fibrate (regardless of the 
level of total cholesterol); BMI — body mass index, OR — odds ratio; CI - confidence interval
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Rozpowszechnienie zaburzeń lipidowych w Polsce. 
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S t r e s z c z e n i e
Wstęp: Polska ciągle należy do krajów o wysokim ryzyku sercowo-naczyniowym. Zaburzenia lipidowe należą do głównych czynników ryzyka 
chorób sercowo-naczyniowych. Dotyczy to przede wszystkim stężenia cholesterolu całkowitego (TC) i cholesterolu frakcji liporotein o niskiej 
gęstości (LDL-C). Dlatego potrzebna jest okresowa ocena występowania dyslipidemii w populacji, by sprawdzić efektywność podejmowanych 
działań prewencyjnych i terapii.
Cel: Celem pracy było zbadanie średniego stężenia lipidów w surowicy krwi oraz ocena częstości występowania, wykrywania i kontroli 
zaburzeń lipidowych w dorosłej populacji Polski.
Metody: Badanie przeprowadzono w reprezentatywnej próbie 1168 mężczyzn (M) i 1245 kobiet (K) w wieku 18–79 lat. W surowicy krwi ozna-
czono stężenie TC, cholesterolu o wysokiej gęstości (HDL-C) i triglicerydów (TG). Korzystając z formuły Friedewalda, wyliczono stężenie LDL-C. 
Wyniki: Średnie stężenie TC u M wynosi 197,1 mg/dl (95% Cl 193,8–200,4), a u K 198,6 mg/dl (195,7–201,5), LDL-C odpowiednio: 123,6 mg/dl 
(120,9–126,2) i 123,7 mg/dl (121,4–126,1), HDL-C: 45,8 mg/dl (44,7–47,0) i 54,1 mg/dl (53,1–55,1), a TG: 140,9 mg/dl (133,0–148,8) 
i 104 mg/dl (99,8–108,2). Stężenie TC ≥ 190 mg/dl stwierdzono u 54,3% badanych. Odsetki są podobne dla M (54,3%) i K (54,4%). Biorąc 
pod uwagę również osoby leczące się z tego powodu, hipercholesterolemia (TC ≥ 190 mg/dl lub terapia statynami) występuje u 61,1% 
(58,2–63,9%) dorosłych Polaków, w tym u 60,8% M (56,4–65,1%) i 61,3% K (57,4–65,1%). Częstość występowania zwiększonego stężenia 
LDL-C (≥ 115 mg/dl) wśród wszystkich badanych wynosi 57,8% (M 58,3%; K 57,3%). Stężenie HDL-C < 40 mg/dl zanotowano u 35,2% 
M, a < 45 mg/dl — u 22,2% K. Hipertriglicerydemia (TG ≥ 150 mg/dl) występuje u 21,1% badanych (M 28,4%; K 14,0%). Nieprawidłowe 
stężenia TC i LDL-C najczęściej stwierdzano u pacjentów w wieku 40–59 lat. Wśród osób z hipercholesterolemią 58,7% (M 61,5%, K 56,0%) 
było nieświadomych jej obecności, 22,0% (M 21,0%, K 24,5%) wiedziało o tym, ale się nie leczyło, 8,1% (M 7,7%, K 8,5%) leczyło się, ale 
nieskutecznie i tylko 10,9% (M 10,7%, K 11,0%) leczyło się skutecznie (TC < 190 mg/dl). Jak wynika z porównań wyników badań NATPOL PLUS 
(2002) i NATPOL 2011, średnie stężenie TC w populacji zmniejszyło się. Jednak korzystne zmiany stężenia TC i LDL-C dotyczą osób po 60. rż.
Wnioski: Wśród dorosłych Polaków w wieku 18–79 lat aż 61% ma hipercholesterolemię. Niepokojące jest, że nieprawidłowe stężenia TC 
i LDL-C dotyczą szczególnie często osób w średnim wieku, a poprawa pod tym względem w latach 2002–2011 dotyczy pacjentów > 60. rż. 
Może to wskazywać i wynikać ze wzrostu przyjmowania statyn przez osoby w tym wieku. Prewencja zaburzeń lipidowych, ich wykrywanie 
i kontrola w Polsce wymagają radykalnej poprawy. 
Słowa kluczowe: lipidy, badanie przekrojowe, metoda reprezentacyjna, rozpowszechnienie, świadomość i kontrola zaburzeń lipidowych
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